300 related articles for article (PubMed ID: 31287426)
21. The FDA Oncology Center of Excellence and precision medicine.
Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
[TBL] [Abstract][Full Text] [Related]
22. Drug-biomarker co-development in oncology - 20 years and counting.
Twomey JD; Brahme NN; Zhang B
Drug Resist Updat; 2017 Jan; 30():48-62. PubMed ID: 28363335
[TBL] [Abstract][Full Text] [Related]
23. An emerging role for cytopathology in precision oncology.
Pauli C; Puca L; Mosquera JM; Robinson BD; Beltran H; Rubin MA; Rao RA
Cancer Cytopathol; 2016 Mar; 124(3):167-73. PubMed ID: 26641771
[TBL] [Abstract][Full Text] [Related]
24. Preanalytic specimen triage: Smears, cell blocks, cytospin preparations, transport media, and cytobanking.
da Cunha Santos G; Saieg MA
Cancer Cytopathol; 2017 Jun; 125(S6):455-464. PubMed ID: 28609003
[TBL] [Abstract][Full Text] [Related]
25. Training in molecular cytopathology testing.
Maxwell P; Salto-Tellez M
Cytopathology; 2018 Feb; 29(1):5-9. PubMed ID: 29148178
[TBL] [Abstract][Full Text] [Related]
26. Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes.
Donovan MJ; Cordon-Cardo C
Mol Diagn Ther; 2017 Apr; 21(2):115-123. PubMed ID: 28000172
[TBL] [Abstract][Full Text] [Related]
27. A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicine.
Heuckmann JM; Thomas RK
Ann Oncol; 2015 Sep; 26(9):1830-1837. PubMed ID: 25899787
[TBL] [Abstract][Full Text] [Related]
28. Precision medicine in pediatric oncology.
Forrest SJ; Geoerger B; Janeway KA
Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
[TBL] [Abstract][Full Text] [Related]
29. Challenges and opportunities of next-generation sequencing: a cytopathologist's perspective.
Vigliar E; Malapelle U; de Luca C; Bellevicine C; Troncone G
Cytopathology; 2015 Oct; 26(5):271-83. PubMed ID: 26399861
[TBL] [Abstract][Full Text] [Related]
30. Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics.
Collins DC; Sundar R; Lim JSJ; Yap TA
Trends Pharmacol Sci; 2017 Jan; 38(1):25-40. PubMed ID: 27871777
[TBL] [Abstract][Full Text] [Related]
31. Update on molecular companion diagnostics - a future in personalized medicine beyond Sanger sequencing.
Campbell MR
Expert Rev Mol Diagn; 2020 Jun; 20(6):637-644. PubMed ID: 32167388
[TBL] [Abstract][Full Text] [Related]
32. Current status of biomarker testing in historically rare, high-unmet-need tumors: soft tissue sarcomas and thyroid cancers.
Schroader B; Kong S; Anderson S; Williamson T; Sireci A; Shields K
Expert Rev Anticancer Ther; 2019 Nov; 19(11):929-938. PubMed ID: 31622558
[No Abstract] [Full Text] [Related]
33. Big data from small samples: Informatics of next-generation sequencing in cytopathology.
Roy-Chowdhuri S; Roy S; Monaco SE; Routbort MJ; Pantanowitz L
Cancer Cytopathol; 2017 Apr; 125(4):236-244. PubMed ID: 27918649
[TBL] [Abstract][Full Text] [Related]
34. KRAS mutation testing in colorectal cancer as an example of the pathologist's role in personalized targeted therapy: a practical approach.
Domagała P; Hybiak J; Sulżyc-Bielicka V; Cybulski C; Ryś J; Domagała W
Pol J Pathol; 2012 Nov; 63(3):145-64. PubMed ID: 23161231
[TBL] [Abstract][Full Text] [Related]
35. Analytic inquiry: Validation and practical considerations.
Berry AB
Cancer Cytopathol; 2017 Jun; 125(S6):465-469. PubMed ID: 28609008
[TBL] [Abstract][Full Text] [Related]
36. Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care.
Schneider D; Bianchini G; Horgan D; Michiels S; Witjes W; Hills R; Plun-Favreau J; Brand A; Lawler M;
Public Health Genomics; 2015; 18(6):349-58. PubMed ID: 26571110
[TBL] [Abstract][Full Text] [Related]
37. The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.
Barbieri CE; Chinnaiyan AM; Lerner SP; Swanton C; Rubin MA
Eur Urol; 2017 Feb; 71(2):237-246. PubMed ID: 27567210
[TBL] [Abstract][Full Text] [Related]
38. Cytopathology in Low Medical Infrastructure Countries: Why and How to Integrate to Capacitate Health Care.
Field AS
Clin Lab Med; 2018 Mar; 38(1):175-182. PubMed ID: 29412881
[TBL] [Abstract][Full Text] [Related]
39. College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference on good laboratory practices in gynecologic cytology: background, rationale, and organization.
Tworek JA; Henry MR; Blond B; Jones BA
Arch Pathol Lab Med; 2013 Feb; 137(2):158-63. PubMed ID: 23368857
[TBL] [Abstract][Full Text] [Related]
40. Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic.
Prudkin L; Nuciforo P
Cell Oncol (Dordr); 2015 Feb; 38(1):39-48. PubMed ID: 25185990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
